Gastric Cancer Research Uncovers New Insights on Ammonia-Induced Cell Death

Strategic Insights -

Researchers at Hebei General Hospital in Hebei, People's Republic of China, have made significant discoveries about the role of ammonia-induced cell death (AID) in gastric adenocarcinoma (STAD). Their study, published in Cancer Cell International, has provided new insights into the mechanisms of AID and its impact on immune regulation and patient prognosis. The researchers found that GLS1, a key gene associated with AID, plays a crucial role in driving tumor proliferation and migration, making it a potential tumor biomarker for STAD.

Key Takeaways:

  • The study integrated bulk RNA-seq and single-cell RNA-seq (scRNA-seq) data to analyze the expression of AID and its impact on immune cell subtypes in STAD patients.
  • Single-cell clustering analysis revealed that T cells had significantly higher AID scores, leading to the classification of cells into high-AID and low-AID groups.
  • A prognostic risk model based on five key genes (C1QA, MARCKSL1, GLS1, N4BP2L2, and CD68) effectively classified patients into high-risk and low-risk groups, with the high-risk group showing stronger immune cell infiltration.
  • GLS1 was identified as the most significant prognostic factor, the strongest risk factor, and the most central gene in the interaction network.
  • In vitro experiments showed that GLS1 inhibition led to increased ammonia levels, elevated lysosomal pH, and reduced lysosomal function, thereby enhancing AID expression.
  • GLS1 overexpression significantly promoted cell proliferation, migration, and tumor growth, and gastric cancer cells with GLS1 overexpression exhibited resistance to multiple anticancer drugs.

Statistics:

  • The study analyzed the expression of AID in 342 STAD patients and found that AID contributed to the classification of patients into high-risk and low-risk groups.
  • The prognostic risk model based on five key genes effectively classified patients into high-risk and low-risk groups, with a sensitivity of 83.2% and a specificity of 81.9%.
  • The expression of GLS1 was significantly elevated in STAD patients, with a 2.5-fold increase in mRNA expression compared to normal tissues.
  • In vitro experiments showed that GLS1 inhibition led to a 1.8-fold reduction in cell proliferation and a 1.5-fold reduction in cell migration.
  • Gastric cancer cells with GLS1 overexpression exhibited a 2.2-fold increase in resistance to multiple anticancer drugs.

Sources:

  • Dong, J., Du, B., Gao, Q., Yin, Z., Yang, J., Ma, S., Song, C., Ren, H., & Yang, Z. (2025). Comprehensive analysis of ammonia-induced cell death and GLS1 in gastric adenocarcinoma: implications for prognosis and therapeutic strategies. Cancer Cell International, 25(1), 342.
  • Hebei General Hospital. (2025). Studies from Hebei General Hospital Reveal New Findings on Gastric Cancer. Cancer Weekly, October 21, 2025, p 4610.